MTG2 as a Causal and Druggable Target in Uveal Melanoma via Mitochondrial DNA Dynamics: Evidence From Functional Validation and DMSA Identification

Key Points

• The aim is to investigate MTG2's role in uveal melanoma (UM) development and assess DMSA's therapeutic potential.
• Integrative genomic analysis to identify relevant genes in UM.
• Experimental validation of MTG2's role in modulating mitochondrial DNA dynamics.
• Evaluation of DMSA's efficacy as a treatment for mitochondrial dysregulation in UM.
• MTG2 is confirmed as a contributor to UM pathogenesis.
• Changes in mitochondrial DNA heteroplasmy and copy number linked to MTG2.
• DMSA shows potential as a therapeutic agent targeting mitochondrial dysfunction in UM.